Carbon Reduction Plan

Publication Date: 01/07/2026

1. Commitment to Achieving Net Zero

TRB Chemedica UK Ltd is committed to achieving Net Zero greenhouse gas emissions (Scope 1, 2 and relevant Scope 3) across its UK operations and value chain by 2050.

TRB Chemedica UK Ltd recognises its responsibility to reduce environmental impacts associated with medical device manufacturing, supply chain activities, distribution, and corporate operations.

This Carbon Reduction Plan (CRP) sets out TRB Chemedica UK Ltd’s current emissions baseline, reduction commitments, planned decarbonisation activities, and governance arrangements to support its transition towards Net Zero.

TRB Chemedica UK Ltd is committed to maintaining high standards of regulatory compliance, product quality, patient safety, and operational resilience while reducing greenhouse gas emissions throughout its value chain.

2. Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases produced prior to the implementation of carbon reduction strategies and provide the reference point against which future emissions reductions will be measured.

2.1 Baseline Statement

The period 1 January 2025 to 31 December 2025 has been selected as TRB Chemedica UK Ltd’s baseline reporting year. This is the first year in which TRB Chemedica UK Ltd has formally measured and reported its greenhouse gas emissions.

As no verified historical emissions data was previously available, the 2025 reporting period has been adopted as the organisation’s baseline year.

Future Carbon Reduction Plans will report progress against this baseline and demonstrate continued progress towards achieving Net Zero.

2.2 Baseline Emissions

Reporting Period: 1 January 2025 – 31 December 2025

TRB Chemedica UK Ltd’s greenhouse gas emissions inventory was calculated using the SME Climate Hub carbon measurement and reporting tool. The assessment applies recognised greenhouse gas accounting principles aligned with the Greenhouse Gas Protocol Corporate Standard and uses appropriate greenhouse gas conversion factors.

TRB Chemedica UK Ltd’s estimated total greenhouse gas emissions for the baseline year were:

2.3 Key Emission Drivers

The principal emission sources identified within TRB Chemedica UK Ltd’s carbon footprint are:

  • Upstream and downstream transportation and distribution
  • Purchased goods and services
  • Packaging materials
  • Electricity and heating consumption
  • Business travel and employee commuting

The assessment demonstrates that Scope 3 emissions represent the majority of TRB Chemedica UK Ltd’s carbon footprint. As a result, future reduction activities will focus primarily on areas where the company can influence emissions reductions, including supply chain engagement, logistics optimisation, sustainable procurement, and packaging improvements.

2.4 Emissions Profile and Value Chain Context

TRB Chemedica UK Ltd is the UK subsidiary of the wider TRB Chemedica International group, a global healthcare organisation with activities spanning medical devices and pharmaceutical products. Within the UK market, TRB Chemedica UK Ltd primarily supports the commercialisation, distribution, and supply of medical device products.

In addition to distributing products supplied by TRB Chemedica International, TRB Chemedica UK Ltd also acts as a distributor for several other medical device companies operating within the healthcare sector. Consequently, the organisation’s emissions profile reflects both its role within a global healthcare supply chain and its select and limited distribution activities undertaken on behalf of external partners.

Due to the nature of its business model, TRB Chemedica UK Ltd has a relatively small direct operational footprint, with limited Scope 1 and Scope 2 emissions associated with UK operational activities, including office-based activities and energy consumption. The majority of the organisation’s greenhouse gas emissions arise from Scope 3 value chain activities, particularly those associated with the supply, transportation, and distribution of medical devices.

The principal contributors to the baseline emissions footprint are:

  • Upstream transportation and distribution associated with the movement of medical devices into the UK supply chain.
  • Downstream transportation and distribution associated with delivery of products to healthcare providers, customers, and distribution partners.
  • Purchased goods and services associated with products distributed within the UK market and operational activities supporting TRB Chemedica UK Ltd’s distribution activities.

TRB Chemedica UK Ltd recognises that, as a distributor, it has limited direct operational control over certain Scope 3 emissions sources. However, the company can influence emissions reductions through supplier engagement, logistics optimisation, sustainable procurement practices, packaging improvements, and collaboration with manufacturing and transport partners.

3. Emissions Reduction Targets

TRB Chemedica UK Ltd has established carbon reduction targets against the 2025 baseline year.

3.1 Near-Term Targets (by 2030)

Against the 2025 baseline, TRB Chemedica UK Ltd commits to:

Scope 1 and Scope 2 Reduction

  • Reduce Scope 1 and 2 emissions by 60% by 2030.
  • Transition to 100% renewable electricity procurement where commercially and technically feasible.
  • Improve energy efficiency through operational improvements.

Scope 3 Reduction

  • Reduce relevant Scope 3 emissions by 24% by 2030, focusing on categories where TRB Chemedica UK Ltd has the ability to influence reductions through supplier engagement, logistics optimisation, procurement decisions and operational improvements.
  • Prioritise reductions in:
    • Transportation and distribution
    • Supplier emissions
    • Packaging impacts
    • Procurement decisions

Additional Environmental Targets

  • Reduce business travel emissions by 50%.
  • Achieve 90% diversion from landfill waste.
  • Improve supplier carbon data collection and reporting

3.2 Long-Term Target (by 2050)

TRB Chemedica UK Ltd commits to:

  • Achieving Net Zero greenhouse gas emissions across UK operations and relevant value chain activities by 2050.
  • Continuing emissions reductions through operational efficiency improvements.
  • Increasing renewable energy use.
  • Collaborating with suppliers and logistics partners to reduce value chain emissions.
  • Using verified carbon removals only for unavoidable residual emissions.

4. Carbon Reduction Projects

4.1 Completed and Ongoing Measures

TRB Chemedica UK Ltd has already implemented a number of measures, including:

  • Hybrid and remote working arrangements where appropriate.
  • Increased use of virtual meetings to reduce travel.
  • Initial LED lighting improvements.
  • Improved waste segregation and recycling processes.
  • Reduction of unnecessary air travel.

4.2 Future Carbon Reduction Initiatives

Logistics and Supply Chain Optimisation

As transportation and distribution represent the largest proportion of emissions, TRB Chemedica UK Ltd will focus on:

  • Consolidating deliveries where possible.
  • Reviewing lower-carbon logistics providers.
  • Improving shipment planning and efficiency.
  • Engaging suppliers on transport emission reduction opportunities.

Sustainable Procurement

Actions will include:

  • Improving supplier carbon emissions data collection.
  • Incorporating environmental considerations into procurement decisions.
  • Encouraging suppliers to establish carbon reduction plans.
  • Identifying lower-carbon alternatives.

Packaging Reduction

TRB Chemedica UK Ltd will explore:

  • Reducing unnecessary packaging materials.
  • Increasing the use of recycled content where appropriate.
  • Packaging optimisation and right-sizing initiatives.
  • Supplier collaboration on packaging improvements.

Renewable Energy and Energy Efficiency

  • Transition to renewable electricity procurement.
  • LED lighting upgrades.
  • Improved heating controls.
  • Smart energy monitoring.
  • Operational energy efficiency improvements.

Business Travel Reduction

TRB Chemedica UK Ltd will:

  • Continue virtual meeting adoption.
  • Promote rail-first travel where practical.
  • Reduce unnecessary domestic flights.
  • Monitor travel-related emissions annually.

Employee Engagement

The company will support carbon reduction through:

  • Sustainability awareness training.
  • Employee engagement initiatives.
  • Energy-saving behaviour programmes.
  • Development of sustainability champions.

5. Governance and Responsibility

This Carbon Reduction Plan has been prepared in accordance with PPN 006 and associated Carbon Reduction Plan reporting requirements.

Emissions have been calculated using the SME Climate Hub carbon measurement tool, applying recognised greenhouse gas accounting principles aligned with the Greenhouse Gas Protocol Corporate Standard.

Appropriate UK Government greenhouse gas conversion factors have been used where applicable.

Overall responsibility for delivery of this Carbon Reduction Plan rests with the Managing Director, supported by the Senior Leadership Team. Progress against emissions targets, carbon reduction initiatives, and improvement actions will be reviewed annually and incorporated into future Carbon Reduction Plans.

6. Declaration and Sign-Off

This Carbon Reduction Plan has been completed in accordance with:

  • PPN 006
  • NHS Carbon Reduction Plan requirements
  • GHG Protocol Corporate Standard
  • Corporate Value Chain (Scope 3) Standard

Emissions have been calculated using the SME Climate Hub carbon measurement tool and appropriate greenhouse gas conversion factors.

This Carbon Reduction Plan has been reviewed and approved by the Board of Directors of TRB Chemedica (UK) Ltd.

Signed:

Mr Ben Dingwall
Managing Director
TRB Chemedica (UK) Ltd

Date: 01/07/2026

References